Prevalence of Immunosuppression Among US Adults

doi:10.1001/jama.2023.28019

. 2024 Mar 12;331(10):880-882.

doi: 10.1001/jama.2023.28019.

Prevalence of Immunosuppression Among US Adults

Melissa L Martinson¹, Jessica Lapham¹

Affiliations

PMID: 38358771
PMCID: PMC10870224
DOI: 10.1001/jama.2023.28019

Prevalence of Immunosuppression Among US Adults

Melissa L Martinson et al. JAMA. 2024.

. 2024 Mar 12;331(10):880-882.

doi: 10.1001/jama.2023.28019.

Authors

Melissa L Martinson¹, Jessica Lapham¹

Affiliation

¹ University of Washington, Seattle.

PMID: 38358771
PMCID: PMC10870224
DOI: 10.1001/jama.2023.28019

No abstract available

Plain language summary

This analysis presents population prevalence estimates of immunosuppression among US adults using data from the 2021 National Health Interview Survey.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Cited by

Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults.
Almeida NC, Parameswaran L, DeHaan EN, Wyper H, Rahman F, Jiang Q, Li W, Patton M, Lino MM, Majid-Mahomed Z, Malkin E, Davis M, Towner WJ, Saharia K, Ilangovan K, Kalinina E, Cooper D, Swanson KA, Anderson AS, Gurtman A, Munjal I. Almeida NC, et al. Vaccines (Basel). 2025 Mar 19;13(3):328. doi: 10.3390/vaccines13030328. Vaccines (Basel). 2025. PMID: 40266222 Free PMC article.
The consequences of SARS-CoV-2 within-host persistence.
Sigal A, Neher RA, Lessells RJ. Sigal A, et al. Nat Rev Microbiol. 2025 May;23(5):288-302. doi: 10.1038/s41579-024-01125-y. Epub 2024 Nov 25. Nat Rev Microbiol. 2025. PMID: 39587352 Review.
Comparative Effectiveness of Antiviral Agents and Monoclonal Antibodies for Early SARS-CoV-2 Therapy in Immunocompromised Patients: A Multicenter Retrospective Cohort Study (March 2021-March 2022).
Vita S, Maffongelli G, Bartoli TA, Benvenuto D, Marocco R, Rosati S, Mazzotta V, Del Borgo C, Mastrorosa I, De Marco P, D'Abramo A, Maggi F, Antinori A, Lichtner M, Nicastri E, Group C. Vita S, et al. Microorganisms. 2025 May 6;13(5):1076. doi: 10.3390/microorganisms13051076. Microorganisms. 2025. PMID: 40431249 Free PMC article.
The gut-lung axis and microbiome dysbiosis in non-tuberculous mycobacterial infections: immune mechanisms, clinical implications, and therapeutic frontiers.
Zhu F, Ying H, Siadat SD, Fateh A. Zhu F, et al. Gut Pathog. 2025 Jun 6;17(1):40. doi: 10.1186/s13099-025-00718-z. Gut Pathog. 2025. PMID: 40481550 Free PMC article. Review.
A Randomized Trial of At-Home COVID-19 Tests, Telemedicine, and Rapid Prescription Delivery for Immunocompromised Individuals.
Vogel JM, Hung TY, Coughlin E, Delgado F, Kheterpal V, Quer G, Topol E. Vogel JM, et al. Mayo Clin Proc Innov Qual Outcomes. 2025 May 22;9(3):100627. doi: 10.1016/j.mayocpiqo.2025.100627. eCollection 2025 Jun. Mayo Clin Proc Innov Qual Outcomes. 2025. PMID: 40503088 Free PMC article.

See all "Cited by" articles

References

1. Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547-2548. doi:10.1001/jama.2016.16477 - DOI - PubMed
1. Wallace BI, Kenney B, Malani PN, Clauw DJ, Nallamothu BK, Waljee AK. Prevalence of immunosuppressive drug use among commercially insured US adults, 2018-2019. JAMA Netw Open. 2021;4(5):e214920-e214920. doi:10.1001/jamanetworkopen.2021.4920 - DOI - PMC - PubMed
1. Link-Gelles R, Weber ZA, Reese SE, et al. . Estimates of bivalent mRNA vaccine durability in preventing COVID-19–associated hospitalization and critical illness among adults with and without immunocompromising conditions—VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579-588. doi:10.15585/mmwr.mm7221a3 - DOI - PMC - PubMed
1. Patel P, Twentyman E, Koumans E, et al. . Information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 infection in the context of currently circulating Omicron sublineages—United States, January 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):128-131. doi:10.15585/mmwr.mm7205e3 - DOI - PMC - PubMed
1. US Centers for Disease Control and Prevention . National Health Interview Survey. Accessed January 14, 2023. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHI...

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

P2C HD042828/HD/NICHD NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547-2548. doi:10.1001/jama.2016.16477 - DOI - PubMed

[2] Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547-2548. doi:10.1001/jama.2016.16477 - DOI - PubMed

[3] Wallace BI, Kenney B, Malani PN, Clauw DJ, Nallamothu BK, Waljee AK. Prevalence of immunosuppressive drug use among commercially insured US adults, 2018-2019. JAMA Netw Open. 2021;4(5):e214920-e214920. doi:10.1001/jamanetworkopen.2021.4920 - DOI - PMC - PubMed

[4] Wallace BI, Kenney B, Malani PN, Clauw DJ, Nallamothu BK, Waljee AK. Prevalence of immunosuppressive drug use among commercially insured US adults, 2018-2019. JAMA Netw Open. 2021;4(5):e214920-e214920. doi:10.1001/jamanetworkopen.2021.4920 - DOI - PMC - PubMed

[5] Link-Gelles R, Weber ZA, Reese SE, et al. . Estimates of bivalent mRNA vaccine durability in preventing COVID-19–associated hospitalization and critical illness among adults with and without immunocompromising conditions—VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579-588. doi:10.15585/mmwr.mm7221a3 - DOI - PMC - PubMed

[6] Link-Gelles R, Weber ZA, Reese SE, et al. . Estimates of bivalent mRNA vaccine durability in preventing COVID-19–associated hospitalization and critical illness among adults with and without immunocompromising conditions—VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579-588. doi:10.15585/mmwr.mm7221a3 - DOI - PMC - PubMed

[7] Patel P, Twentyman E, Koumans E, et al. . Information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 infection in the context of currently circulating Omicron sublineages—United States, January 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):128-131. doi:10.15585/mmwr.mm7205e3 - DOI - PMC - PubMed

[8] Patel P, Twentyman E, Koumans E, et al. . Information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 infection in the context of currently circulating Omicron sublineages—United States, January 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):128-131. doi:10.15585/mmwr.mm7205e3 - DOI - PMC - PubMed

[9] US Centers for Disease Control and Prevention . National Health Interview Survey. Accessed January 14, 2023. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHI...

[10] US Centers for Disease Control and Prevention . National Health Interview Survey. Accessed January 14, 2023. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHI...

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prevalence of Immunosuppression Among US Adults

Affiliation

Prevalence of Immunosuppression Among US Adults

Authors

Affiliation

Plain language summary

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Plain language summary

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources